543 related articles for article (PubMed ID: 21746920)
1. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
[TBL] [Abstract][Full Text] [Related]
2. p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.
Lam HC; Baglini CV; Lope AL; Parkhitko AA; Liu HJ; Alesi N; Malinowska IA; Ebrahimi-Fakhari D; Saffari A; Yu JJ; Pereira A; Khabibullin D; Ogorek B; Nijmeh J; Kavanagh T; Handen A; Chan SY; Asara JM; Oldham WM; Diaz-Meco MT; Moscat J; Sahin M; Priolo C; Henske EP
Cancer Res; 2017 Jun; 77(12):3255-3267. PubMed ID: 28512249
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
4. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
5. Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide.
Parkhitko AA; Priolo C; Coloff JL; Yun J; Wu JJ; Mizumura K; Xu W; Malinowska IA; Yu J; Kwiatkowski DJ; Locasale JW; Asara JM; Choi AM; Finkel T; Henske EP
Mol Cancer Res; 2014 Jan; 12(1):48-57. PubMed ID: 24296756
[TBL] [Abstract][Full Text] [Related]
6. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
Hino O; Kobayashi T
Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
[TBL] [Abstract][Full Text] [Related]
7. Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Filippakis H; Belaid A; Siroky B; Wu C; Alesi N; Hougard T; Nijmeh J; Lam HC; Henske EP
Sci Rep; 2018 Sep; 8(1):14161. PubMed ID: 30242175
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
Medvetz D; Priolo C; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
10. Tuberous sclerosis-2 (TSC2) regulates the stability of death-associated protein kinase-1 (DAPK) through a lysosome-dependent degradation pathway.
Lin Y; Henderson P; Pettersson S; Satsangi J; Hupp T; Stevens C
FEBS J; 2011 Jan; 278(2):354-70. PubMed ID: 21134130
[TBL] [Abstract][Full Text] [Related]
11. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
[TBL] [Abstract][Full Text] [Related]
12. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration.
Reith RM; Way S; McKenna J; Haines K; Gambello MJ
Neurobiol Dis; 2011 Jul; 43(1):113-22. PubMed ID: 21419848
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
15. Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition.
Barnes EA; Kenerson HL; Jiang X; Yeung RS
Am J Pathol; 2010 Oct; 177(4):1765-78. PubMed ID: 20813961
[TBL] [Abstract][Full Text] [Related]
16. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
18. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
[TBL] [Abstract][Full Text] [Related]
20. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]